All Phenotypes Gt(ROSA)26Sor<tm1Jus> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo} Tg(Mx1-cre)1Cgn/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA	MGI:5517427
cn2	Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo} Tg(MMTV-cre)4Mam/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB	MGI:5517429
cn3	Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor⁺ Tg(Mx1-cre)1Cgn/0	involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA	MGI:5517428
cn4	Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor⁺ Tg(Lck-icre)3779Nik/0	involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA/2	MGI:5517426
cn5	Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor⁺ Tg(MMTV-cre)4Mam/0	involves: C57BL/6J * C57BL/6N * FVB/N	MGI:5517430

Allelic Composition	Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo} Tg(Mx1-cre)1Cgn/0
Genetic Background	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^tm1Jus mutation (0 available); any Gt(ROSA)26Sor mutation (1046 available)
Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo} mutation (10 available); any Gt(ROSA)26Sor mutation (1046 available)
Tg(Mx1-cre)1Cgn mutation (10 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

abnormal common lymphocyte progenitor cell morphology ( J:202090 )

• 20-fold increase in pIpC-treated mice

increased hematopoietic stem cell number ( J:202090 )

• expanded long term hematopoietic stem-like cells in pIpC-treated mice

Allelic Composition	Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo} Tg(MMTV-cre)4Mam/0
Genetic Background	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

abnormal common lymphocyte progenitor cell morphology ( J:202090 )

• 20-fold increase

increased hematopoietic stem cell number ( J:202090 )

• expanded long term hematopoietic stem-like cells

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:202090 )

• median survival is 41 days post pIpC treatment

immune system

enlarged thymus ( J:202090 )

• in diseased pIpC-treated mice

abnormal thymus physiology ( J:202090 )

• lymphoid infiltration in the thymus at 6 months in pIpC-treated mice

enlarged spleen ( J:202090 )

• in diseased pIpC-treated mice

abnormal leukocyte morphology ( J:202090 )

• monomorphic, enlarged white blood cells with a high nuclear:chromatin ratio (consistent with leukemic blasts) at 6 months in pIpC-treated mice

decreased pro-B cell number ( J:202090 )

• in pIpC-treated mice

arrested B cell differentiation ( J:202090 )

• nearly all B cells are arrested in the early pro-B stage of pIpC-treated mice

decreased double-positive T cell number ( J:202090 )

• in the thymus of pIpC-treated mice

decreased B cell number ( J:202090 )

• in the spleen of pIpC-treated mice

decreased mature B cell number ( J:202090 )

• in pIpC-treated mice

decreased pre-B cell number ( J:202090 )

• in pIpC-treated mice

increased leukocyte cell number ( J:202090 )

• at 6 months in pIpC-treated mice

increased CD8-positive, alpha-beta T cell number ( J:202090 )

• in the thymus of pIpC-treated mice

increased single-positive T cell number ( J:202090 )

• immature single positive cells in the thymus of pIpC-treated mice

increased large unstained cell number ( J:202090 )

• large, unstained cells (abnormal blasts) in the peripheral blood at 6 months in pIpC-treated mice

intermingled spleen red and white pulp ( J:202090 )

• disrupted separation between white and red pulp by infiltrating lymphoblasts at 6 months in pIpC-treated mice

enlarged lymph nodes ( J:202090 )

• in diseased pIpC-treated mice

increased inflammatory response ( J:202090 )

• lymphoid infiltration in the spleen, interstitial and perivascular space of the kidney, perivascular cuffs in the liver, meninges surrounding the brain, thymus, stomach and intestine at 6 months in pIpC-treated mice

intestinal inflammation ( J:202090 )

• lymphoid infiltration in the intestine at 6 months in pIpC-treated mice

stomach inflammation ( J:202090 )

• lymphoid infiltration in the stomach at 6 months in pIpC-treated mice

meningitis ( J:202090 )

• lymphoid infiltration in the meninges surrounding the brain at 6 months in pIpC-treated mice

liver inflammation ( J:202090 )

• lymphoid infiltration in the perivascular cuffs in the liver at 6 months in pIpC-treated mice

kidney inflammation ( J:202090 )

• lymphoid infiltration in the interstitial and perivascular space of the kidney at 6 months in pIpC-treated mice

digestive/alimentary system

intestinal inflammation ( J:202090 )

• lymphoid infiltration in the intestine at 6 months in pIpC-treated mice

stomach inflammation ( J:202090 )

• lymphoid infiltration in the stomach at 6 months in pIpC-treated mice

neoplasm

increased acute lymphoblastic leukemia incidence ( J:202090 )

• pIpC-treated mice rapidly develop and succumb to acute leukemia

behavior/neurological

lethargy ( J:202090 )

growth/size/body

distended abdomen ( J:202090 )

• in diseased pIpC-treated mice

enlarged kidney ( J:202090 )

• in diseased pIpC-treated mice

enlarged liver ( J:202090 )

• in diseased pIpC-treated mice

enlarged spleen ( J:202090 )

• in diseased pIpC-treated mice

respiratory system

respiratory distress ( J:202090 )

liver/biliary system

enlarged liver ( J:202090 )

• in diseased pIpC-treated mice

liver inflammation ( J:202090 )

• lymphoid infiltration in the perivascular cuffs in the liver at 6 months in pIpC-treated mice

nervous system

meningitis ( J:202090 )

• lymphoid infiltration in the meninges surrounding the brain at 6 months in pIpC-treated mice

renal/urinary system

enlarged kidney ( J:202090 )

• in diseased pIpC-treated mice

kidney inflammation ( J:202090 )

• lymphoid infiltration in the interstitial and perivascular space of the kidney at 6 months in pIpC-treated mice

hematopoietic system

enlarged thymus ( J:202090 )

• in diseased pIpC-treated mice

abnormal thymus physiology ( J:202090 )

• lymphoid infiltration in the thymus at 6 months in pIpC-treated mice

enlarged spleen ( J:202090 )

• in diseased pIpC-treated mice

anemia ( J:202090 )

• slightly at 6 months in pIpC-treated mice

thrombocytopenia ( J:202090 )

• severely at 6 months in pIpC-treated mice

abnormal leukocyte morphology ( J:202090 )

• monomorphic, enlarged white blood cells with a high nuclear:chromatin ratio (consistent with leukemic blasts) at 6 months in pIpC-treated mice

decreased pro-B cell number ( J:202090 )

• in pIpC-treated mice

arrested B cell differentiation ( J:202090 )

• nearly all B cells are arrested in the early pro-B stage of pIpC-treated mice

decreased double-positive T cell number ( J:202090 )

• in the thymus of pIpC-treated mice

decreased B cell number ( J:202090 )

• in the spleen of pIpC-treated mice

decreased mature B cell number ( J:202090 )

• in pIpC-treated mice

decreased pre-B cell number ( J:202090 )

• in pIpC-treated mice

increased leukocyte cell number ( J:202090 )

• at 6 months in pIpC-treated mice

increased CD8-positive, alpha-beta T cell number ( J:202090 )

• in the thymus of pIpC-treated mice

increased single-positive T cell number ( J:202090 )

• immature single positive cells in the thymus of pIpC-treated mice

increased large unstained cell number ( J:202090 )

• large, unstained cells (abnormal blasts) in the peripheral blood at 6 months in pIpC-treated mice

intermingled spleen red and white pulp ( J:202090 )

• disrupted separation between white and red pulp by infiltrating lymphoblasts at 6 months in pIpC-treated mice

endocrine/exocrine glands

enlarged thymus ( J:202090 )

• in diseased pIpC-treated mice

abnormal thymus physiology ( J:202090 )

• lymphoid infiltration in the thymus at 6 months in pIpC-treated mice

Allelic Composition	Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor⁺ Tg(Lck-icre)3779Nik/0
Genetic Background	involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^tm1Jus mutation (0 available); any Gt(ROSA)26Sor mutation (1046 available)
Tg(Lck-icre)3779Nik mutation (2 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

immune system

immune system phenotype ( J:202090 )

N	• mice exhibit normal T cell differentiation

neoplasm

neoplasm ( J:202090 )

N	• mice do not develop leukemia

Allelic Composition	Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor⁺ Tg(MMTV-cre)4Mam/0
Genetic Background	involves: C57BL/6J * C57BL/6N * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sor^tm1Jus mutation (0 available); any Gt(ROSA)26Sor mutation (1046 available)
Tg(MMTV-cre)4Mam mutation (2 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:202090 )

• median survival is 64 days

immune system

enlarged thymus ( J:202090 )

• in diseased mice

abnormal thymus physiology ( J:202090 )

• lymphoid infiltration in the thymus at 6 months

enlarged spleen ( J:202090 )

• in diseased mice

abnormal leukocyte morphology ( J:202090 )

• monomorphic, enlarged white blood cells with a high nuclear:chromatin ratio (consistent with leukemic blasts) at 6 months

decreased pro-B cell number ( J:202090 )

arrested B cell differentiation ( J:202090 )

• nearly all B cells are arrested in the early pro-B stage

decreased double-positive T cell number ( J:202090 )

• in the thymus

decreased B cell number ( J:202090 )

• in the spleen

decreased mature B cell number ( J:202090 )

decreased pre-B cell number ( J:202090 )

increased leukocyte cell number ( J:202090 )

• at 6 months

increased CD8-positive, alpha-beta T cell number ( J:202090 )

• in the thymus

increased single-positive T cell number ( J:202090 )

• immature single positive cells in the thymus

increased large unstained cell number ( J:202090 )

• large, unstained cells (abnormal blasts) in the peripheral blood at 6 months

intermingled spleen red and white pulp ( J:202090 )

• disrupted separation between white and red pulp by infiltrating lymphoblasts at 6 months

enlarged lymph nodes ( J:202090 )

• in diseased mice

increased inflammatory response ( J:202090 )

• lymphoid infiltration in the spleen, interstitial and perivascular space of the kidney, perivascular cuffs in the liver, meninges surrounding the brain, thymus, stomach and intestine at 6 months

intestinal inflammation ( J:202090 )

• lymphoid infiltration in the intestine at 6 months

stomach inflammation ( J:202090 )

• lymphoid infiltration in the stomach at 6 months

meningitis ( J:202090 )

• lymphoid infiltration in the meninges surrounding the brain at 6 months

liver inflammation ( J:202090 )

• lymphoid infiltration in the perivascular cuffs in the liver at 6 months

kidney inflammation ( J:202090 )

• lymphoid infiltration in the interstitial and perivascular space of the kidney at 6 months

digestive/alimentary system

intestinal inflammation ( J:202090 )

• lymphoid infiltration in the intestine at 6 months

stomach inflammation ( J:202090 )

• lymphoid infiltration in the stomach at 6 months

neoplasm

increased acute lymphoblastic leukemia incidence ( J:202090 )

• mice rapidly develop and succumb to acute leukemia

behavior/neurological

lethargy ( J:202090 )

growth/size/body

distended abdomen ( J:202090 )

• in diseased mice

enlarged kidney ( J:202090 )

• in diseased mice

enlarged liver ( J:202090 )

• in diseased mice

enlarged spleen ( J:202090 )

• in diseased mice

respiratory system

respiratory distress ( J:202090 )

liver/biliary system

enlarged liver ( J:202090 )

• in diseased mice

liver inflammation ( J:202090 )

• lymphoid infiltration in the perivascular cuffs in the liver at 6 months

nervous system

meningitis ( J:202090 )

• lymphoid infiltration in the meninges surrounding the brain at 6 months

renal/urinary system

enlarged kidney ( J:202090 )

• in diseased mice

kidney inflammation ( J:202090 )

• lymphoid infiltration in the interstitial and perivascular space of the kidney at 6 months

hematopoietic system

enlarged thymus ( J:202090 )

• in diseased mice

abnormal thymus physiology ( J:202090 )

• lymphoid infiltration in the thymus at 6 months

enlarged spleen ( J:202090 )

• in diseased mice

anemia ( J:202090 )

• slightly at 6 months

thrombocytopenia ( J:202090 )

• severely at 6 months

abnormal leukocyte morphology ( J:202090 )

• monomorphic, enlarged white blood cells with a high nuclear:chromatin ratio (consistent with leukemic blasts) at 6 months

decreased pro-B cell number ( J:202090 )

arrested B cell differentiation ( J:202090 )

• nearly all B cells are arrested in the early pro-B stage

decreased double-positive T cell number ( J:202090 )

• in the thymus

decreased B cell number ( J:202090 )

• in the spleen

decreased mature B cell number ( J:202090 )

decreased pre-B cell number ( J:202090 )

increased leukocyte cell number ( J:202090 )

• at 6 months

increased CD8-positive, alpha-beta T cell number ( J:202090 )

• in the thymus

increased single-positive T cell number ( J:202090 )

• immature single positive cells in the thymus

increased large unstained cell number ( J:202090 )

• large, unstained cells (abnormal blasts) in the peripheral blood at 6 months

intermingled spleen red and white pulp ( J:202090 )

• disrupted separation between white and red pulp by infiltrating lymphoblasts at 6 months

endocrine/exocrine glands

enlarged thymus ( J:202090 )

• in diseased mice

abnormal thymus physiology ( J:202090 )

• lymphoid infiltration in the thymus at 6 months

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 09/30/2025 MGI 6.24